@VPrasadMDMPH What you're saying is a statement of the current state but likely completely wrong in the very near future. AI helping human clinicians make better decisions should already be happening now. Have you read the EXALT-1 trial paper?; https://t.c
This development led to the EXALT-1 clinical trial and its exciting results:
RT @CD_AACR: Attending the #AACR23 session on #FunctionalPrecisionMedicine in Oncology? #ICYMI by speaker @PhilippStaber— Functional Precis…
RT @CD_AACR: Attending the #AACR23 session on #FunctionalPrecisionMedicine in Oncology? #ICYMI by speaker @PhilippStaber— Functional Precis…
RT @CD_AACR: Attending the #AACR23 session on #FunctionalPrecisionMedicine in Oncology? #ICYMI by speaker @PhilippStaber— Functional Precis…
RT @CD_AACR: Attending the #AACR23 session on #FunctionalPrecisionMedicine in Oncology? #ICYMI by speaker @PhilippStaber— Functional Precis…
RT @CD_AACR: Attending the #AACR23 session on #FunctionalPrecisionMedicine in Oncology? #ICYMI by speaker @PhilippStaber— Functional Precis…
RT @CD_AACR: Attending the #AACR23 session on #FunctionalPrecisionMedicine in Oncology? #ICYMI by speaker @PhilippStaber— Functional Precis…
RT @CD_AACR: Attending the #AACR23 session on #FunctionalPrecisionMedicine in Oncology? #ICYMI by speaker @PhilippStaber— Functional Precis…
RT @CD_AACR: Attending the #AACR23 session on #FunctionalPrecisionMedicine in Oncology? #ICYMI by speaker @PhilippStaber— Functional Precis…
Attending the #AACR23 session on #FunctionalPrecisionMedicine in Oncology? #ICYMI by speaker @PhilippStaber— Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies #ExceptionalResponders. https:/
RT @GregVladimer: (3/5) We developed an extensible computational framework, embedded multiple data streams from these disease-relevant prim…
(3/5) We developed an extensible computational framework, embedded multiple data streams from these disease-relevant primary samples including single-cell functional response data from our proprietary deep learning-driven image analysis pipeline (see https
The EXALT-1 work was previously published in Cancer Discovery in 2022 @CD_AACR; https://t.co/0CrvMfedkh $EXAI 3/6
RT @ElizSMcKenna: ICYMI in @CD_AACR: #FunctionalPrecisionMedicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers an…
RT @ElizSMcKenna: ICYMI in @CD_AACR: #FunctionalPrecisionMedicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers an…
RT @ElizSMcKenna: ICYMI in @CD_AACR: #FunctionalPrecisionMedicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers an…
ICYMI in @CD_AACR: #FunctionalPrecisionMedicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders @CK5haus @TPemovska Ingrid Simonitsch-Klupp @giuliosf @BerendSnijder @PhilippStaber et al #ASH22 ht
RT @empiricancer: #Functionalprecisionmedicine (FPM) is already providing benefits to patients. A single-cell FPM approach provided 54% of…
RT @empiricancer: #Functionalprecisionmedicine (FPM) is already providing benefits to patients. A single-cell FPM approach provided 54% of…
#Functionalprecisionmedicine (FPM) is already providing benefits to patients. A single-cell FPM approach provided 54% of patients with improved survival compared to previous therapies. Read about it in Cancer Discovery at: https://t.co/JB4Ng5t5Ky
Therapies should be based on response properties of tumors, not transcriptome pt 5: https://t.co/mSrTUycCGy
I’m going to have to read this one 🤓 Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders | @AACR https://t.co/HngnXHziT7
There is absolutely value to selecting the most effective therapy on the first try, particularly in oncology. https://t.co/rMGFZEKym9 8/? https://t.co/Ms3xLvEROF
Super proud!
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological Cancers and Identifies #ExceptionalResponder…
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological Cancers and Identifies #ExceptionalResponder…
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological Cancers and Identifies #ExceptionalResponder…
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological Cancers and Identifies #ExceptionalResponder…
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological Cancers and Identifies #ExceptionalResponder…
RT @DrTonyLetai: @TheSFPM
@TheSFPM
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological Cancers and Identifies #ExceptionalResponder…
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological Cancers and Identifies #ExceptionalResponder…
Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological Cancers and Identifies #ExceptionalResponders by @CK5haus @TPemovska Ingrid Simonitsch-Klupp @giuliosf @BerendSnijder @PhilippStaber et al. https://t.co/wmRHScXJ4b @MedUni_W
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders [Research Articles] https://t.co/JYbFYkbN0F https://t.co/Ivhj67oAaa
RT @imedverse: Online First | Cancer Discovery Functional #PrecisionMedicine Provides #clinical Benefit in Advanced Aggressive #Hematolog…
Online First | Cancer Discovery Functional #PrecisionMedicine Provides #clinical Benefit in Advanced Aggressive #Hematologic #Cancers and Identifies Exceptional #Responders. @CD_AACR @imedverse https://t.co/hbMOqftuQn https://t.co/V7JTl0R6L0
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional…
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. https://t.co/PKAG6jod2w Philipp B. Staber, Christoph Kornauth and colleagues @MedUni_Wien https://t.co/iJTDEglLLg
RT @ElizSMcKenna: ICYMI in @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological Cancers and Identifi…
RT @precisiondiagn4: RT @ElizSMcKenna: ICYMI in @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological Cancers #ExceptionalResponders @CK5haus @TPemovska @giuliosf @BerendSnijder @PhilippStaber et al @MedUni_Wien @CeMM_News @ETH_en #ASH21
RT @ElizSMcKenna: ICYMI in @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological Cancers and Identifi…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological Cancers and Identifi…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological Cancers and Identifi…
ICYMI in @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Hematological Cancers and Identifies #ExceptionalResponders @CK5haus @TPemovska @giuliosf @BerendSnijder @PhilippStaber et al @MedUni_Wien @CeMM_News @ETH_en #ASH21 http
RT @7MaxxChatsko: EXALT-1 trial evaluated $EXAI tech platform to optimize treatment decisions for advanced blood cancers. Similar value-add…
EXALT-1 trial evaluated $EXAI tech platform to optimize treatment decisions for advanced blood cancers. Similar value-add as liquid biopsies (something investors are more familiar with), but significantly more scaleable. The results were pretty stunning.
RT @CeMM_News: The underlying technology was developed in the laboratory of CeMM Director Giulio Superti-Furga (@gsf_lab). Read the full p…
RT @RUT_hhshark: Agressiveな血液腫瘍に対する精密医療：EXALT-1試験 /Cancer Discovery https://t.co/xlm9yveRSs Exscientia社の技術で治療をパーソナライズ （様々な染色画像をシングルセルデータ解析ス…
RT @RUT_hhshark: Agressiveな血液腫瘍に対する精密医療：EXALT-1試験 /Cancer Discovery https://t.co/xlm9yveRSs Exscientia社の技術で治療をパーソナライズ （様々な染色画像をシングルセルデータ解析ス…
Agressiveな血液腫瘍に対する精密医療：EXALT-1試験 /Cancer Discovery https://t.co/xlm9yveRSs Exscientia社の技術で治療をパーソナライズ （様々な染色画像をシングルセルデータ解析スコアリング＋ex vivoで薬効評価かな） 半分の症例は前治療よりＰＦＳが1.3倍、奏効した症例の4割が超奏効
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptiona…
RT @LukasKenner: Together with the #CeMM and the #Snijder Lab at #IMSB, we published the first successful study using functional drug testi…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @LukasKenner: Together with the #CeMM and the #Snijder Lab at #IMSB, we published the first successful study using functional drug testi…
Together with the #CeMM and the #Snijder Lab at #IMSB, we published the first successful study using functional drug testing for the personalized treatment of patients with aggressive blood cancers @VetmeduniVienna @S4F_AT https://t.co/0L6qP1ezsf
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @NatRevClinOncol: Prospective EXALT study demonstrates that a image-based single-cell functional precision medicine approach provides cl…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
Makes sense. How scalable it is for future development is what I’m wondering.
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptiona…
Important new study by @CK5haus @PhilippStaber and colleagues
RT @seiichi_mori: Nice approach. “We prospectively tested an image-based single-cell functional precision medicine (scFPM) approach to guid…
Nice approach. “We prospectively tested an image-based single-cell functional precision medicine (scFPM) approach to guide treatments in 143 patients with advanced aggressive hematologic cancers“
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptiona…
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptiona…
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptiona…
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptiona…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptiona…
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders. https://t.co/fXJtCZTVQA @CK5haus, @TPemovska, Ingrid Simonitsch-Klupp, @giuliosf, @BerendSnijder, @PhilippStaber, a
RT @NatRevClinOncol: Prospective EXALT study demonstrates that a image-based single-cell functional precision medicine approach provides cl…
RT @NatRevClinOncol: Prospective EXALT study demonstrates that a image-based single-cell functional precision medicine approach provides cl…
Prospective EXALT study demonstrates that a image-based single-cell functional precision medicine approach provides clinical benefit in pts with advanced-stage aggressive haematological cancers and identifies exceptional responders: https://t.co/0aV3Y0oXN
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
@RaieBekele Here it is: https://t.co/wxiLg4KZzb Sorry, we've already put it in an earlier tweet and forgot to put it here again.
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
RT @jsoriamd: #Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biop…
#Personalized medicine utilizes features of individual patients' tumor to guide #therapy. Here drug profiling of patient biopsies was tested in 143 pts with hematologic cancers. 39% of the pts were treated according to this approach with promising results.
Treating leukemia informed by high-throughput microscopy drug screens of patient material. Clearly a glimpse into the future of personalized medicine by @snijderlab, @exscientiaAI et al.
RT @PhilippStaber: Is direct therapy matching possible and of benefit for our patients? YES, please check out our latest paper in @CD_AACR…
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders https://t.co/vTIN8aczpL
RT @giuliosf: What looks like "yet another study" = breakthrough result of a long investment in my laboratory exploring innovative ways to…
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders https://t.co/zQzrrwHBcr
RT @ElizSMcKenna: Now online in @CD_AACR: Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Blood Cancers and…
The underlying technology was developed in the laboratory of CeMM Director Giulio Superti-Furga (@gsf_lab). Read the full publication (DOI: 10.1158/2159-8290.CD-21-0538)👇https://t.co/hfr8Yy2KyT